Oct 12 (Reuters) - Valeant Pharmaceuticals International Inc (NYSE:VRX) VRX.TO
* Ortho Dermatologics announces two-year findings from pivotal phase 3 study of Siliq (brodalumab) injection data demonstrating long-term efficacy profile
* Ortho Dermatologics - Over a two-year trial, a pasi 100 response rate was reached by 59 percent of a sub-analysis group of patients
* ortho Dermatologics - At week 120, siliq continued to be generally well-tolerated with safety profile comparable to that observed in 52-week period